1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2017.
http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention
.
2. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73.
3. American Academy of Allergy, Asthma & Immunology. The prevalence of severe refractory asthma. 2014.
http://www.aaaai.org/global/latest-research-summaries/New-Research-from-JACI-In-Practice/refractory-asthma
.
4. US Food and Drug Administration. Xolair® (omalizumab) for injection, for subcutaneous use. 2016.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf
.
5. European Medicines Agency. Xolair 75 mg powder and solvent for solution for injection. 2016.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf
.